A phase II study of paclitaxel in platinum pretreated ovarian cancer. A hellenic cooperative oncology group study

• Published in: European journal of cancer (1990) Vol. 33; no. 1; pp. 160 - 163
• Main Authors: Aravantinos, G., Skarlos, D.V., Kosmidis, P., Athanassiades, A., Bafaloukos, D., Giannakakis, T., Karpathios, S., Fountzilas, G.
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 1997; Elsevier
• Subjects: Adult; Aged; Antineoplastic agents; Antineoplastic Agents, Phytogenic - adverse effects; Antineoplastic Agents, Phytogenic - therapeutic use; Biological and medical sciences; Chemotherapy; Drug Resistance, Neoplasm; Female; Humans; Medical sciences; Middle Aged; ovarian cancer chemotherapy; Ovarian Neoplasms - drug therapy; Paclitaxel - adverse effects; Paclitaxel - therapeutic use; paclitaxel chemotherapy; Patient Compliance; Pharmacology. Drug treatments; Platinum Compounds - therapeutic use; Survival Rate; Treatment Outcome; ovarian cancer chemotherapy; paclitaxel chemotherapy; Antineoplastic agent; Human; Carcinoma; Malignant tumor; Cisplatin; Female genital diseases; Ovarian diseases; Ovary; Chemotherapy; Treatment; Taxane derivatives; Phase II trial; Paclitaxel; Pretreatment; Platinum II Complexes
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/S0959-8049(96)00366-8

Paclitaxel was administered at a dose of 175 mg/m 2 in a 3-hour infusion every 3 weeks in platinum pretreated patients with ovarian cancer. 51 patients with a median age of 57 years entered the study. 33 (65%) presented with stage III and 18 (35%) with stage IV disease. 39 patients (76%) were previously treated with only one and 12 (24%) with two regimens. The median interval from the last previous chemotherapy was 4 months (range, 1–65). Ninety-eight per cent of the planned dose of paclitaxel was actually delivered. Overall and complete response rate was 26% ( 13 51 ) and 16% ( 8 51 ), respectively. All complete responses were observed among patients previously treated with only one regimen. Median time to progression was 10.26 months (range, 4.9–25.2+) and median survival 15.6 months (range, 1.3–27.1+). Factors influencing survival were performance status and the number of previous regimens.